ASCO 2026: Spevatamig Opens a New Path in Pancreatic Cancer Immunotherapy

2026-08-10 07:19:45

At the 62nd ASCO Annual Meeting, targeted therapies, ADCs and immunotherapies advanced on three fronts against pancreatic cancer. Phanes Therapeutics' CLDN18.2/CD47 bispecific antibody spevatamig, combined with GnP chemotherapy, showed striking first-line data in metastatic pancreatic cancer, and its innate immunity–enhancing mechanism may break the "cold tumor" dilemma.